The biopharma landscape is forever changing, and with it, a demand from both patients and investors for the rapid development and progression of drug products to market. Analytical testing is a crucial part of this process and must be carefully considered when striving for a speedy development timeline while maintaining safety for patients. Well-designed analytical testing of biologics is...
How can Bora Biologics help to support your next biologics project? Having a robust Cell Line Development (CLD) strategy is the foundation of biologic production that can propel a project, helping to streamline production while mitigating risk. A tailored and optimized cell line can be instrumental in overcoming development and manufacturing challenges and achieving a competitive advantage in...
The rapidly growing numbers of monoclonal antibodies (mAbs), fusion proteins and biosimilars produced by the pharma industry have greatly improved patient care and resulted in a proliferation of innovative treatment options. To date, there are over 100 biosimilars [1, 2], 162 mAbs [3] and over 11 fusion proteins [4] approved for therapeutic use. These new therapeutic proteins are often more...
September 21-22, 2023
Hyatt Regency New Brunswick
Table 91